Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances
Journal of Clinical Medicine · 17.09.2026 · 15 (18) · 7238
DOI: 10.3390/jcm15187238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.09.2026. Verfasst von Zuzanna Betiuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lubli…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Endometriosis affects 190 million women worldwide, so there is a need for accessible and more comprehensive knowledge regarding the pharmacotherapeutic options that can be offered to patients. This systematic review (2019–2025) synthesizes research results regarding the efficacy and safety of dienogest (DNG) and GnRH antagonists, while also summarizing research on new directions in endometriosis treatment.
Methods
Following PRISMA 2020 guidelines, we searched Medline for clinical evidence on established standards and emerging therapies. A structured narrative synthesis was performed. Quality was assessed using Cochrane RoB 2 and ROBINS-I tools.
Results
A total of 44 out of 926 records were analyzed. The review confirms the efficacy of DNG as a first-line treatment for endometriosis. Relugolix combination therapy appears to be a more effective and safer option than elagolix or relugolix monotherapy in reducing dysmenorrhea and pelvic pain. Research concerning immunotherapy for endometriosis (using tocilizumab, anakinra, bevacizumab, and anti-CD47 antibodies) is subject to a high risk of bias and very low GRADE certainty. Nevertheless, these findings may serve as a foundation for further studies, which are necessary to evaluate their efficacy and safety in the treatment of endometriosis.
Conclusions
DNG is generally well-tolerated, but further studies are needed to unequivocally determine the impact of DNG on BMD loss and cancer risk. Research on GnRH antagonists indicates their increasing role in the future management of endometriosis. There are new perspectives in endometriosis pharmacotherapy—including immunotherapy; however, there is a fundamental need for their further development and evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Students' Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland.
- 1st Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16 St., 20-081 Lublin, Poland.
ORCID-Profile: Zuzanna Betiuk, Martyna Błażyca, Martyna Bartoszczyk, Katarzyna Kutyła, Natalia Gierulska
Zitieren
APA
Betiuk, Z., Błażyca, M., Bartoszczyk, M., Kutyła, K., Gierulska, N., Tarkowski, R., & Kułak, K. (2026). Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances. Journal of Clinical Medicine, 15(18), 7238. https://doi.org/10.3390/jcm15187238
Vancouver
Betiuk Z, Błażyca M, Bartoszczyk M, Kutyła K, Gierulska N, Tarkowski R, et al. Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances. Journal of Clinical Medicine. 2026;15(18):7238. doi:10.3390/jcm15187238
BibTeX
@article{Betiuk2026,
author = {Betiuk, Zuzanna and Błażyca, Martyna and Bartoszczyk, Martyna and Kutyła, Katarzyna and Gierulska, Natalia and Tarkowski, Rafał and Kułak, Krzysztof},
title = {Current Evidence and Emerging Directions in Endometriosis Pharmacotherapy: A Systematic Review of Recent Advances},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {18},
pages = {7238},
doi = {10.3390/jcm15187238}
}
EUVIMED